Effectively, it means medicines and medical products available in India are safer than what is available in American and European markets. Nearly 10.5% of the samples collected by WHO’s Global Surveillance and Monitoring System for substandard and falsified medical products (GSMS) between 2013-17 failed quality test, says the report released on Tuesday. It defines falsified medical products as those that misrepresent identity, composition or source. The growing global trade in medicines has also opened door to drugs, vaccines and other medical products that do not meet quality standards and are even toxic at times. Launched in 2013 by the WHO, the Global Surveillance and Monitoring System aims to improve the quality of medical products and aid in member countries.

Source: Hindustan Times November 29, 2017 02:42 UTC